DE69032855D1 - Antiidiotypischer antikörper, der eine immunantwort gegen ein glykosphingolipid induziert und seine verwendung - Google Patents

Antiidiotypischer antikörper, der eine immunantwort gegen ein glykosphingolipid induziert und seine verwendung

Info

Publication number
DE69032855D1
DE69032855D1 DE69032855T DE69032855T DE69032855D1 DE 69032855 D1 DE69032855 D1 DE 69032855D1 DE 69032855 T DE69032855 T DE 69032855T DE 69032855 T DE69032855 T DE 69032855T DE 69032855 D1 DE69032855 D1 DE 69032855D1
Authority
DE
Germany
Prior art keywords
glycosphingolipid
immune response
antiidiotypical
antibody inducing
provides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69032855T
Other languages
English (en)
Other versions
DE69032855T2 (de
Inventor
Paul Chapman
Alan Houghton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Memorial Sloan Kettering Cancer Center
Original Assignee
Sloan Kettering Institute for Cancer Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sloan Kettering Institute for Cancer Research filed Critical Sloan Kettering Institute for Cancer Research
Application granted granted Critical
Publication of DE69032855D1 publication Critical patent/DE69032855D1/de
Publication of DE69032855T2 publication Critical patent/DE69032855T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • C07K16/4266—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig against anti-tumor receptor Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6873—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an immunoglobulin; the antibody being an anti-idiotypic antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE69032855T 1989-05-25 1990-05-25 Antiidiotypischer antikörper, der eine immunantwort gegen ein glykosphingolipid induziert und seine verwendung Expired - Fee Related DE69032855T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35703789A 1989-05-25 1989-05-25
PCT/US1990/003061 WO1990014104A1 (en) 1989-05-25 1990-05-25 Anti-idiotypic antibody which induces an immune response against a glycosphingolipid and use thereof

Publications (2)

Publication Number Publication Date
DE69032855D1 true DE69032855D1 (de) 1999-02-04
DE69032855T2 DE69032855T2 (de) 1999-08-12

Family

ID=23404043

Family Applications (3)

Application Number Title Priority Date Filing Date
DE69032855T Expired - Fee Related DE69032855T2 (de) 1989-05-25 1990-05-25 Antiidiotypischer antikörper, der eine immunantwort gegen ein glykosphingolipid induziert und seine verwendung
DE199090909554T Pending DE473721T1 (de) 1989-05-25 1990-05-25 Antiidiotypischer antikoerper, der eine immunantwort gegen ein glykosphingolipid induziert und seine verwendung.
DE69034087T Expired - Fee Related DE69034087T2 (de) 1989-05-25 1990-05-25 Antiidiotypischer Antikörper, der ein Immunantwort gegen ein Glykosphingolipid induziert und seine Verwendung

Family Applications After (2)

Application Number Title Priority Date Filing Date
DE199090909554T Pending DE473721T1 (de) 1989-05-25 1990-05-25 Antiidiotypischer antikoerper, der eine immunantwort gegen ein glykosphingolipid induziert und seine verwendung.
DE69034087T Expired - Fee Related DE69034087T2 (de) 1989-05-25 1990-05-25 Antiidiotypischer Antikörper, der ein Immunantwort gegen ein Glykosphingolipid induziert und seine Verwendung

Country Status (10)

Country Link
US (1) US5529922A (de)
EP (3) EP0473721B1 (de)
JP (1) JP3392860B2 (de)
AT (2) ATE174799T1 (de)
CA (1) CA2057010C (de)
DE (3) DE69032855T2 (de)
DK (2) DK0884329T3 (de)
ES (2) ES2127186T3 (de)
HK (1) HK1014658A1 (de)
WO (1) WO1990014104A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6432402B1 (en) 1989-05-25 2002-08-13 Sloan-Kettering Institute For Cancer Research Anti-idiotypic antibody which induces an immune response against a glycosphingolipid and use thereof
US6805862B1 (en) 1989-05-25 2004-10-19 Sloan-Kattering Institute For Cancer Research Anti-idiotypic antibody which induces an immune response against a glycosphingolipid and use thereof
US5268454A (en) * 1991-02-08 1993-12-07 La Jolla Pharmaceutical Company Composition for inducing humoral anergy to an immunogen comprising a t cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic carrier
US20030035797A1 (en) * 1992-01-27 2003-02-20 Sloan-Kettering Institute For Cancer Research Anti-idiotypic antibody which induces an immune response against a glycosphingolipid and use thereof
US5874085A (en) * 1993-11-10 1999-02-23 Henry M. Jackson Foundation For The Advancement Of Military Medicine Vaccine for enhanced production of IgA antibodies
CU22420A1 (es) * 1993-12-29 1996-01-31 Centro Inmunologia Molecular Composicion vacunal para el desarrollo de una respuesta contra gangliosidos n glicolilados y su uso para el tratamiento del cancer
US6149921A (en) * 1993-12-29 2000-11-21 Centro De Inmunologia Molecular Vaccine compositions for eliciting an immune response against N-acetylated gangliosides and their use for cancer treatment
US5612030A (en) * 1995-01-17 1997-03-18 University Of Kentucky Research Foundation Anti-idiotype monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma
US5977316A (en) * 1995-01-17 1999-11-02 The Board Of Trustees Of The University Of Kentucky Monoclonal antibody 1A7 and related polypeptides
US5935821A (en) * 1995-01-17 1999-08-10 Board Of Trustees Of The University Of Kentucky Polynucleotides related to monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma
US5792455A (en) * 1996-03-21 1998-08-11 Sloan-Kettering Institute For Cancer Research Anti-idiotypic antibody vaccines
US6355244B1 (en) 1997-11-17 2002-03-12 University Of Kentucky Research Foundation Methods and compositions for the treatment of psoriasis
PT1071700E (pt) 1998-04-20 2010-04-23 Glycart Biotechnology Ag Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
US6989276B2 (en) 2001-05-10 2006-01-24 Battelle Energy Alliance, Llc Rapid classification of biological components
USRE46351E1 (en) 2001-05-10 2017-03-28 Battelle Energy Alliance, Llc Antibody profiling sensitivity through increased reporter antibody layering
CA2838062C (en) * 2001-08-03 2015-12-22 Roche Glycart Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
BRPI0617500B8 (pt) * 2005-10-17 2021-07-27 Spidertech A Div Of Stoecker & Associates A Subsidiary Of The Dermatology Center Llc kit de imunoensaio para a detecção de veneno de loxosceles reclusa
US20080286881A1 (en) * 2007-05-14 2008-11-20 Apel William A Compositions and methods for combining report antibodies
WO2011022103A2 (en) * 2009-08-18 2011-02-24 Medical College Of Georgia Research Institute, Inc. Ganglioside epitopes for treating guillain-barre syndrome
US8969009B2 (en) * 2009-09-17 2015-03-03 Vicki S. Thompson Identification of discriminant proteins through antibody profiling, methods and apparatus for identifying an individual
US9410965B2 (en) * 2009-09-17 2016-08-09 Battelle Energy Alliance, Llc Identification of discriminant proteins through antibody profiling, methods and apparatus for identifying an individual

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE32833E (en) * 1982-03-01 1989-01-17 President And Fellows Of Harvard College Screening vaccines and immunization process
EP0134868A1 (de) * 1983-08-26 1985-03-27 Anda Biologicals Glutaraldehyd-aktivierte einzellige Organismen als feste Träger für Sensibilisierungsmittel und Gebrauch von sensibilisierten einzelligen Organismen
US4918164A (en) * 1987-09-10 1990-04-17 Oncogen Tumor immunotherapy using anti-idiotypic antibodies
US5614610A (en) * 1984-12-21 1997-03-25 Oncogen Tumor immunotherapy using anti-idiotypic antibodies
EP0268640A4 (de) * 1986-05-07 1989-11-30 Sloan Kettering Inst Cancer Impfstoff zur stimulierung oder erhöhung von antikörpern gegen gm2.
US4849509A (en) * 1987-02-20 1989-07-18 The Wistar Institute Monoclonal antibodies against melanoma-associated antigens and hybrid cell lines producing these antibodies
IT1217314B (it) * 1987-02-20 1990-03-22 Sclavo Spa Nonapeptide sintetico ad attivita'adiuvante capace di potenziare in vivo la risposta anticorporale
AU1711888A (en) * 1987-04-24 1988-12-02 Biogen, Inc. Immunotherapeutic methods and compositions
US4900547A (en) * 1987-10-23 1990-02-13 University Of British Columbia Method to immunize mammals against tumors

Also Published As

Publication number Publication date
EP0473721A1 (de) 1992-03-11
DE69034087T2 (de) 2004-05-06
EP0473721B1 (de) 1998-12-23
JPH05500600A (ja) 1993-02-12
CA2057010A1 (en) 1990-11-26
ATE243713T1 (de) 2003-07-15
DE473721T1 (de) 1993-04-29
ATE174799T1 (de) 1999-01-15
DE69034087D1 (de) 2003-07-31
EP1334984A1 (de) 2003-08-13
WO1990014104A1 (en) 1990-11-29
DK0884329T3 (da) 2003-10-20
DK0473721T3 (da) 1999-08-23
US5529922A (en) 1996-06-25
CA2057010C (en) 2002-08-06
EP0884329B1 (de) 2003-06-25
EP0473721A4 (de) 1994-03-23
ES2127186T3 (es) 1999-04-16
EP0884329A1 (de) 1998-12-16
JP3392860B2 (ja) 2003-03-31
DE69032855T2 (de) 1999-08-12
ES2207768T3 (es) 2004-06-01
HK1014658A1 (en) 1999-09-30

Similar Documents

Publication Publication Date Title
DE69032855D1 (de) Antiidiotypischer antikörper, der eine immunantwort gegen ein glykosphingolipid induziert und seine verwendung
DE59000652D1 (de) Verwendung von umsetzungsprodukten von alkenylspirobislactonen und aminen als paraffindispergatoren.
DE69015952D1 (de) Spiegeleinrichtung für den Bereich der UV- und Röntgenstrahlen.
DE69028346D1 (de) Härtbare Siliconmassen
IT8319396A0 (it) Procedimento per il trattamento termico per leghe nicraly per uso come materiali per forni ceramici e forni da trattamento termico.
ATE82574T1 (de) Bis-aza-bicyclische anxiolytica und antidepressiva.
NO901046D0 (no) Rekombinat proteinreseptor.
ITMI910754A0 (it) Procedimento e disposizione per condensare sostanze vaporose
IT1141240B (it) Procedimento e dispositivo per fissare pastiglie d'usura ad attrito
IT8719292A0 (it) Composizione di anticorpi monoclonali umani cross-protettivi.
FI910572A (fi) Regnmaetare med anordning som paovisar tilltaeppning.
IT1140561B (it) Dispositivo sollevatore particolarmente per lo spostamento di pianali di mobili e simili
DE3689948D1 (de) Monoklonale antikörper und testverfahren.
DK75289A (da) Fremgangsmaade til fremstilling af antihypercholesterolemiske tetrazolforbindelser og mellemprodukter derved
IT8249377A0 (it) Fermaglio perfezionato per articolidi gioielleria e simili
DE69014132D1 (de) Reibbeläge und trägereinheit.
IT1226729B (it) Dispositivo di fissaggio per il cinturino di sostegno di un ombrello.
IT8834015V0 (it) Dispositivo di fissaggio di elementi sensori come termostati e simili.
MX9202642A (es) Anticuerpos monoclonales y antigeno para melanoma humano.
DE3650327D1 (de) Monoklonaler Antikörper gegen die polymorphe Determinante B27 des HLA.
FI903304A (fi) Foerfarande foer framstaellning av kaffe med laog taethet.
NO912509D0 (no) Fremgangsmaate for fremstilling av substituerte acykliske nukleosider og mellomprodukter derav.
IT219509Z2 (it) Contenitore-raccoglitore particolarmente per orologi, bracciali e simili
DE59003265D1 (de) Verwendung von nor-verapamil und nor-gallopamil als antiarteriosklerotica.
IT219526Z2 (it) Dispositivo per il supporto e lo scorrimento di tende e simili

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee